Potential benefit of high-dose intravenous vitamin C for coronavirus disease 2019 pneumonia
Chin Med J (Engl)
.
2022 Jan 5;135(1):23-25.
doi: 10.1097/CM9.0000000000001746.
Authors
Bing Zhao
1
,
Mengjiao Li
1
,
Yun Ling
2
,
Yibing Peng
3
,
Jun Huang
4
,
Hongping Qu
5
,
Yuan Gao
6
,
Yingchuan Li
7
,
Bijie Hu
8
,
Shuihua Lu
9
,
Hongzhou Lu
2
,
Wenhong Zhang
10
,
Enqiang Mao
1
Affiliations
1
Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
2
Department of Infectious Disease, Shanghai Public Health Clinical Center, Shanghai 201508, China.
3
Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
4
Shanghai Institute of Hypertension, Shanghai 200025, China.
5
Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
6
Department of Critical Care Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200217, China.
7
Department of Critical Care Medicine, The Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China.
8
Department of Infectious Disease, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
9
Tuberculosis Department of Shanghai Public Health Clinical Center, Shanghai 201508, China.
10
Department of Infectious Disease of Shanghai Huashan Hospital, Fudan University, Shanghai 200040, China.
PMID:
34873081
PMCID:
PMC8850810
DOI:
10.1097/CM9.0000000000001746
No abstract available
MeSH terms
Administration, Intravenous
Ascorbic Acid / therapeutic use
COVID-19*
Humans
Pneumonia*
SARS-CoV-2
Substances
Ascorbic Acid